Psychedelic drugs
can exert potent anti-inflammatory effects. However,
anti-inflammatory effects do not appear to correlate with behavioral
activity, suggesting different underlying mechanisms. We hypothesized
that the distinct structural features of psychedelics underlie functionally
selective mechanisms at the target 5-HT2A receptor to elicit
maximal anti-inflammatory effects. In order to test this hypothesis,
we developed a new rat-based screening platform for allergic asthma.
Next, we investigated 21 agonists at the 5-HT2A receptor
from the three primary chemotypes (phenylalkylamine, ergoline, and
tryptamine) for their ability to prevent airways hyperresponsiveness as a measure of pulmonary
inflammation. Furthermore, we assessed each drug for in vitro activation of the canonical signaling pathway, calcium mobilization,
from the 5-HT2A receptor. We find that the drug 2,5-dimethoxyphenethylamine
(2C-H) represents the pharmacophore for anti-inflammatory activity
and identify structural modifications that are either permissive or
detrimental to anti-inflammatory activity. Additionally, there is
no correlation between the ability of a particular psychedelic to
activate intracellular calcium mobilization and to prevent the symptoms
of asthma or with behavioral potencies. Our results support the notions
that specific structural features mediate functional selectivity underlying
anti-inflammatory activity and that relevant receptor activated pathways
necessary for anti-inflammatory activity are different from canonical
signaling pathways. Our results inform on the nature of interactions
between ligands at the 5-HT2A receptor as they relate to
anti-inflammatory activity and are crucial for the development of
new 5-HT2A receptor agonists for anti-inflammatory therapeutics
in the clinic that may be devoid of behavioral activity.